MedTrace Logo

Effects of Aerobic Cycling Training in Patients With Gynecologic Cancer-related Lower Extremity Lymphedema

NCT06200948 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 63

Last updated 2024-05-24

No results posted yet for this study

Summary

Comparison of complete decongestive treatment and complete decongestive treatment + cycling ergometry treatment in patients with gynecologic cancer-related lower extremity lymphedema in terms of quality of life, lower extremity functionality and lower extremity volume measurement

Conditions

  • Lymphedema
  • Lymphedema, Lower Limb
  • Gynecologic Cancer

Interventions

OTHER

Aerobic Exercise

While the patients in non-cycling group will get only complete decongestive treatment (CDT) for 3 weeks, the patients in cycling group will get CDT+cycling ergometry treatment for 3 weeks. Cycling ergometry treatment will be performed with Voit AT-200 Black Collection horizontal bike for 20 minutes. Exercise intensity will be adjusted to %40-59 of heart rate reserve (HRR).

OTHER

Complete Decongestive Treatment

While the patients in non-cycling group will get only complete decongestive treatment (CDT) for 3 weeks, the patients in cycling group will get CDT+cycling ergometry treatment for 3 weeks. Cycling ergometry treatment will be performed with Voit AT-200 Black Collection horizontal bike for 20 minutes. Exercise intensity will be adjusted to %40-59 of heart rate reserve (HRR).

Sponsors & Collaborators

  • Ankara City Hospital Bilkent

    lead OTHER

Principal Investigators

  • Onur Kara, M.D. · Health Sciences University, Ankara Bilkent City Hospital

  • Gül Mete Civelek, M.D. · Health Sciences University, Ankara Bilkent City Hospital

  • Meltem Dalyan, M.D. · Health Sciences University, Ankara Bilkent City Hospital

  • Cansu Şahbaz Pirinççi, Pt. (PhD.) · Health Sciences University, Gulhane Physiotherapy and Rehabilitation Faculty

  • Rabia Tarlabölen, Pt. · Health Sciences University, Ankara Bilkent City Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-15
Primary Completion
2024-05-23
Completion
2024-05-23

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06200948 on ClinicalTrials.gov